drug development

Paving the way in botanical psychedelic drug development.

In-house Development Program

We are demonstrating the safety and efficacy of botanical psychedelic drug candidates for the first time in human clinical trials:

Our drug candidates are led through trials by Principal Investigator,  Dr. Joshua Woolley, MD/Ph.D., Director of the Translational Psychedelic Research (TrPR) Program at the University of California San Francisco.

Sponsor
Phase I
Phase II
Start
Intervention
Indication
Location
This Is the first FDA-approved study to administer botanical psychedelic drug candidates. It will assess the benefits of directly administering psilocin orally (PEX020) and sublingually (PEX030).
07 2022
UCSF (IIT)
PEX010, 020, 030
Healthy Volunteers
USA/San Francisco
This study is designed to establish safety and efficacy of PEX010 in a clinical population. In addition it is designed to overcome a major deficiency in psychedelic clinical research by employing a novel control condition.
Q1 2023*
Filament Health
PEX010 (25mg)
Major Depressive Disorder
USA/San Francisco
Approval Pending
Trial Approved
*Anticipated start date
Partnership network development program
Revenue-Generating Licensing Partnerships

Filament has partnered with leading researchers worldwide to advance natural psychedelic research and generate revenue.

We believe that our botanical drugs could be effective in many therapeutic areas and that research on multiple indications is necessary. Our patented technology provides an attractive platform whereby third-party drug developers can leverage our IP and regulatory expertise by using Filament’s drug candidates in their clinical trials.
This provides Filament with the opportunity to obtain near-term milestone-based revenue and royalties upon commercialization.



Sponsor
Phase I
Phase II
Start
Intervention
Indication
Location
Q4 2022*
Psyence Group
PEX010 (25mg)
Palliative Care
UK/London
Q4 2022*
Cybin Therapeutics
PEX010 (25mg)
Depression
Canada/Vancouver
Q4 2022*
EntheoTech Bioscience
PEX010 (25mg)
Opioid Tapering
Canada/Okanagan
Q4 2022*
EntheoTech Bioscience
PEX010 (25mg)
Chronic Pain/Depression
Canada/Okanagan
Q3 2022
ATMA Journey Centers
PEX010 (25mg)
Therapist Training
Canada/Alberta
Q2 2023*
ATMA Journey Centers
PEX010 (25mg)
COVID Mental Health Concerns – Frontline HC
Canada/ Alberta
Approval Pending
Trial Approved
*Anticipated start date
Academic AND Philanthropic Low-cost Partnerships

We provide low- or no-cost study drugs to academic researchers and retain safety data for in-house programs.

This is one way in which we give back to the psychedelic research community. We also gain insights into new indications and safety data for future regulatory filings.

Sponsor
Phase I
Phase II
Start
Intervention
Indication
Location
Q4 2022*
University of Toronto
PEX010 (1mg)
Depression
Canada/Toronto
Q1 2023*
University of Liège
PEX010 (25mg)
Coma
Belgium
Q1 2023*
(Withheld)
PEX010 (25mg)
Alcohol Use Disorder
EU
Q2 2023*
University of Calgary
PEX010 (1mg)
Alcohol Use Disorder
Canada/ Alberta
Approval Pending
Trial Approved
*Anticipated start date
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.